Merck & Co

News

Ex-Merck & Co scientist accused of stealing trade secrets co...

A former Merck & Co scientist could face up to 10 years in prison after he was accused of stealing trade secrets relating to drugs including the cancer immunotherapy Keytruda by US auth

News

The liver is a vital organ of the digestive system present in vertebrates and some other animals. It has a wide range of functions, including detoxification, protein synthesis, and production of biochemicals necessary for digestion.

High hopes as Inventiva takes NASH contender into phase 3

Analysts are continuing to back Inventiva’s lanifibranor as a potential “best-in-class” drug for the fatty liver disease NASH, as the company prepares for the launch of a phase 3 trial in s

News

Merck cuts $1bn deal with Janux for cancer T-cell therapies

In a deal that could top $1 billion, Merck & Co has teamed up with US biotech Janux Therapeutics to bring T-cell immunotherapies to cancer patients.

Views & Analysis

The top 5 pharma M&A deals of 2020

2020’s M&A activity hasn’t quite reached the heights of last year’s, where two pharma mega-mergers –

News

Merck & Co adds COVID-19 drug to pipeline with OncoImmune bu...

Merck & Co is to buy US biotech OncoImmune for at least $425m, adding a potential new therapy for COVID-19 to its pipeline.

News

Merck & Co/Eisai eye kidney cancer use for immunotherapy com...

Merck & Co and Eisai are to file results from a phase 3 trial testing a combination of the former’s immunotherapy Keytruda, combined with the latter’s cancer drug Lenvima in untreated p

Ex-Merck & Co scientist accused of stealing trade secrets co...

High hopes as Inventiva takes NASH contender into phase 3

Merck cuts $1bn deal with Janux for cancer T-cell therapies

The top 5 pharma M&A deals of 2020

Merck & Co adds COVID-19 drug to pipeline with OncoImmune bu...

Merck & Co/Eisai eye kidney cancer use for immunotherapy com...

CDC panel votes to scrap hepatitis B birth dose advice

How to meet your physicians where they are online

Merck &amp; Co

Editor's Picks

Merck & Co